[
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock",
    "summary": "CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.",
    "url": "https://finnhub.io/api/news?id=2c15ba78ae1b15d0aab44ccd3993e3f60805a73d176a8d25ac9ff362c9564b66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755789300,
      "headline": "CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock",
      "id": 136467931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.",
      "url": "https://finnhub.io/api/news?id=2c15ba78ae1b15d0aab44ccd3993e3f60805a73d176a8d25ac9ff362c9564b66"
    }
  },
  {
    "ts": null,
    "headline": "Why investors should buy Amphenol & avoid Vertex Pharmaceuticals",
    "summary": "Zacks Investment Management senior client portfolio manager Brian Mulberry joins Market Domination with Josh Lipton to discuss why he recommends buying Amphenol (APH) and why he says investors should stay away from Vertex Pharmaceuticals (VRTX). To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=2a0ad29c8af28f95c3bd80fd769d89deb118870f29a1d089f2f718c7d4e50624",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755774017,
      "headline": "Why investors should buy Amphenol & avoid Vertex Pharmaceuticals",
      "id": 136467868,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Zacks Investment Management senior client portfolio manager Brian Mulberry joins Market Domination with Josh Lipton to discuss why he recommends buying Amphenol (APH) and why he says investors should stay away from Vertex Pharmaceuticals (VRTX). To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=2a0ad29c8af28f95c3bd80fd769d89deb118870f29a1d089f2f718c7d4e50624"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755771900,
      "headline": "Hartford Healthcare Fund Q2 2025 Commentary",
      "id": 136458913,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/685006799/image_685006799.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=f8b7703fb46da00d8ea965f9f056688fcf2528cb789b78bb6f1c7c7ea46efb79"
    }
  }
]